The primary aim of this study was to investigate the changes in alexithymia levels in fibromyalgia patients over a six-month period following a combined treatment and to assess the relationship between changes in fibromyalgia symptom severity and changes in alexithymia levels. Specifically, the study sought to determine if improvements in fibromyalgia symptoms, as measured by the Visual Analog Scale (VAS), were associated with reductions in alexithymia, as measured by the Toronto Alexithymia Scale-20 (TAS-20).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Alexithymia Level
Timeframe: From enrollment to the end of treatment at 6 months
VAS score
Timeframe: From enrollment to the end of treatment at 6 months
Correlations between baseline values and post-treatment changes
Timeframe: From enrollment to the end of treatment at 6 months